Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 08:16:47 AM Sat, 7 Jul 2018   Contact Information Clifford Stephan Associated Profiles  Research Associate Professor and Director, Center for Translational Cancer Research, Institute of Biosciences and Technology -TAMHSC   Center for Translational Cancer Research    cstephan@tamu.edu     713-677-7456    Web Link    Drug Discovery, High Throughput Drug Screening, Combinatorial Drug Screening    Associated Profiles Professional Preparation Research and Expertise Affiliations Appointments  Professional Preparation  Degree Major Institution Year  PhD Pharmacology Vanderbilt University    BA Chemistry & Molecular Biology Vanderbilt University    Research and Expertise Research Interests   A unique resource providing researchers from Texas A&M and the Texas Medical Center with access to state-of-the-art tools to support the discovery of new drugs and new treatments for some of the most devastating diseases of our time. The Combinatorial Drug Discovery Program resides in the Texas A&M Health Science Center's Institute of Biosciences and Technology. This core provides industry standard high throughput screening and microscopy capabilities to scientists carrying out chemical and genomic biochemical and drug discovery research. The core supports investigators from all of the institutions in and around the Houston/Galveston region and with pharmaceutical and biotechnology partners. The core provides many benefits, such as access to an automated infrastructure that is capable of supporting both biochemical and cell-based screens. The core also provides ready access to a collection of nearly 60,000 drugs, investigational agents and small molecules. Our collections of test agents include current FDA-approved clinical candidates and off-patent drugs exhibiting the 'drug-like' qualities of acceptable solubility, desirable ADME/toxicology properties and adequate bioavailability. These properties are important for rapid advancement of new agents into successful preclinical and clinical trials by discovering new therapeutic vulnerabilities alone or in combinations. We also have collections of mechanistically annotated informer sets that are pathway specific modulators for studying mechanism of action. The core also has collections of natural products and diverse sets of small molecules that can be interrogated for new target discovery. The greatest benefit of the core; however, is its fulltime professional staff. The screening team is composed of highly experienced biologists, biochemists, pharmacologists and bio-informaticians with pharmaceutical industry and academic experience. Each project is individually evaluated and a team of scientists from the core is created to fit the specific needs of the project from assay development through primary, secondary and orthogonal screening. The team is committed to providing an integrated and highly collaborative program with every investigator.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia GCC Consortium for Antimicrobial Resistance (GCC AMR) GCC Mental Health Research Cluster  Training Grants The Cancer Therapeutics Training Program (CTTP)  Appointments Title Department / School Institution Research Associate Professor Center for Translational Cancer Research Institute of Biosciences and Technology -TAMHSC

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.